ABVX

Abivax
ABVX
Market cap $371M

5.85 USD

-0.20

3.31%

Updated Apr 3, 3:29 PM EDT

1 day

-3.31%

5 days

-12.16%

1 month

-20.19%

3 months

-21.48%

6 months

-43.15%

Year to date

-19.75%

1 year

-60.84%

5 years

-29.52%

10 years

-29.52%

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Employees: 69

Healthcare Biotechnology

0

Funds holding %

of 7,398 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

20% more funds holding

Funds holding: 40 [Q3] → 48 (+8) [Q4]

3.88% more ownership

Funds ownership: 43.26% [Q3] → 47.14% (+3.88%) [Q4]

30% less capital invested

Capital invested by funds: $313M [Q3] → $219M (-$94.3M) [Q4]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

105%

upside

Avg. target

$26

344%

upside

High target

$33

464%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Morgan Stanley Judah Frommer 45% 1-year accuracy 5 / 11 met price target	105%upside $12	Equal-Weight Assumed	20 Mar 2025
Citizens Capital Markets Jason Butler 19% 1-year accuracy 8 / 42 met price target	464%upside $33	Market Outperform Reiterated	18 Mar 2025
JMP Securities Roy Buchanan 24% 1-year accuracy 6 / 25 met price target	464%upside $33	Market Outperform Reiterated	10 Jan 2025

See Analyst Rankings

Financial journalist opinion

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March 24, 2025. The Universal Registration Document includes the 2024 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, as of December 31, 2024. The 2024 financial statements, approved by the Company's Board of Directors on March 20, 2025, have been audited by the Company's statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities, respectively, on March 24, 2025.

Abivax Announces Full Year 2024 Financial Results

Zacks Investment Research

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?

The consensus price target hints at a 360.5% upside potential for Abivax SA Sponsored ADR (ABVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m.

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Zacks Investment Research

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet

The mean of analysts' price targets for Abivax SA Sponsored ADR (ABVX) points to a 427.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet

Zacks Investment Research

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks

Abivax SA Sponsored ADR (ABVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks

Abivax Publishes 2025 Financial Calendar

Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press Release Universal Registration Document (Euronext) Annual Report on Form 20-F Monday, June 2, 2025 (after US Market closes) 2025 Q1 Financial Results (as of March 31, 2025) Press Release Report on Form 6-K Friday, June 6, 2025 2025 Annual General Meeting (AGM) Live meeting in Paris, France Monday, August 11, 2025 (after US Market closes) 2025 Half-Year Business and Financial Report (as of June 30, 2025) Press Release Half-Year Financial Report (Euronext) Report on Form 6-K Monday, December 15, 2025 (after US Market closes) 2025 Q3 Financial Results (as of September 30, 2025) Press Release Report on Form 6-K About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director of the Company effective on December 31, 2024. Dr. Philippe Pouletty's decision is directly related to his appointment last week as Chairman and acting Chief Executive Officer of a French listed biotechnology company in the field of plastics recycling.

Abivax Announces a Change to the Composition of its Board of Directors

See News Rankings

Charts implemented using Lightweight Charts™